In the research, we observed significantly higher percentages of CD19+ CD38intermediateCD24intermediate B cells in patients with DM compared to those in healthy individuals (66.98 ± 2.321% vs 58.25 ± 1.836%, p < 0.001). This evidence concerns the gene CD19 and dermatomyositis.